Insight

Ahmad Ozair: Work from Adult Brain Tumor Consortium

Photo taken from Ahmad Ozair/X

Aug 10, 2024, 11:52

Ahmad Ozair: Work from Adult Brain Tumor Consortium

Ahmad Ozair, Postdoctoral Research Fellow in Neurosurgery at University of Maryland, shared a post on X:

“Out in this month’s issue of Clinical Cancer Research, our work from Adult Brain Tumor Consortium, led by Manmeet Ahluwalia– synthetic lethality by combining DNA alkylating agent (TMZ) with DNA repair inhibitor (TRC102) in BERT trial.”

Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT

Authors: Manmeet S Ahluwalia, Ahmad Ozair, Jan Drappatz, Xiaobu Ye, Sen Peng, Matthew Lee, Sanhita Rath, Harshil Dhruv, Yue Hao, Michael E Berens, Tobias Walbert, Matthias Holdhoff, Glenn J Lesser, Timothy F Cloughesy, Andrew E Sloan, Naoko Takebe, Marta Couce, David M Peereboom, Burt Nabors, Patrick Y Wen, Stuart A Grossman, and Lisa R Rogers.

TRC102 + TMZ

For more information.

Source: Ahmad Ozair/X

Adult Brain Tumor Consortium Ahmad Ozair cancer Clinical Cancer Research Jan Drappatz Lisa R Rogers Manmeet Ahluwalia Manmeet S. Ahluwalia OncoDaily Oncology Patrick Y Wen Stuart A Grossman

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology